Search Results
Your search for ,foR matches 32898 pages
Showing 4351 - 4400First-Line Pembrolizumab Plus Gemcitabine/Cisplatin May Improve Overall Survival in Advanced Biliary Tract Cancer
The addition of pembrolizumab to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 clinical trial, which were presented by Robin Katie Kelley, MD, and colleagues at the...
Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable NSCLC: AEGEAN Trial
Treatment-naive patients with resectable non–small cell lung cancer (NSCLC) who received neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response compared with those who received neoadjuvant chemotherapy alone,...
Mitesh J. Borad, MD, on Hepatobiliary Cancers: Management Updates
Mitesh J. Borad, MD, of the Mayo Clinic Comprehensive Cancer Center, discusses the expanding number of options in immunotherapies for patients with advanced hepatobiliary cancers, applying targeted treatments to this disease, and the importance of genomic profiling in patients with biliary tract...
Addressing Racial Disparities in Cancer Pain Management: A Potential Role for Music Therapy
Guest Editor’s Note: Despite its high prevalence, cancer pain remains undertreated. Racial disparities present further challenges to assessing and managing pain. Music therapy, a nonpharmacologic intervention, has been documented to be effective in controlling cancer pain. In this article, Kevin T. ...
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
As reported in JAMA Oncology by Tang et al, the phase II EXTEND (External Beam Radiation to Eliminate Nominal Metastatic Disease) trial has shown that the addition of metastasis-directed therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic...
MRD and KMT2A Fusion Partners in Predicting Outcomes of Childhood KMT2A-Rearranged Acute Myeloid Leukemia
In a retrospective study reported in the Journal of Clinical Oncology, van Weelderen et al, of the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG), found that KMT2A fusion partners and measurable residual disease (MRD) at end of induction phase 2 were independent predictors of...
Addition of Abiraterone Acetate and Prednisone to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Michael J. Morris, MD, and colleagues, the phase III Alliance A031201 trial has shown no significant improvement in overall survival with the addition of abiraterone acetate and prednisone to enzalutamide as first-line treatment for metastatic...
Pathologic Complete Response and Outcomes in Localized Soft-Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy
In an analysis reported in JAMA Oncology, Wang et al found that pathologic complete response (pCR) was associated with improved outcomes among patients with localized soft-tissue sarcoma receiving neoadjuvant chemoradiotherapy or radiotherapy. The analysis included data from patients from two RTOG...
Belzutifan Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma Previously Treated With PD-1 or PD-L1 Inhibitors
In a U.S. phase II trial reported in The Lancet Oncology, Toni K. Choueiri, MD, and colleagues found that the combination of the hypoxia-inducible factor 2α inhibitor belzutifan and the VEGFR kinase inhibitor cabozantinib showed promising activity in patients with advanced clear cell renal cell...
Confirmatory Mediastinoscopy vs Immediate Resection After Endosonography for Resectable NSCLC
In a trial (MEDIASTrial) reported in the Journal of Clinical Oncology, Bousema et al found that immediate lung tumor resection after negative systematic endosonography was noninferior to confirmatory mediastinoscopy in the detection of unforeseen N2 disease in patients with non–small cell lung...
Update on Withdrawal of Ibrutinib Accelerated Approvals for MCL and MZL in the United States
AbbVie announced that it intends to voluntarily withdraw, in the United States, accelerated ibrutinib (Imbruvica) approvals for patients with mantle cell lymphoma (MCL) who have received at least one prior therapy as well as patients with marginal zone lymphoma (MZL) who require systemic therapy...
Pragmatica-Lung Trial Begins Enrolling Patients With NSCLC Who Did Not Respond to Previous Therapy
The National Cancer Institute (NCI) announced that it has helped launch the randomized phase III Pragmatica-Lung trial examining the efficacy of ramucirumab plus pembrolizumab in treating patients with advanced non–small cell lung cancer (NSCLC). The new study is one of the first NCI-supported...
New Study Examines Cancer-Related Mortality Rates During First Year of COVID-19 Pandemic
U.S. mortality rates with cancer as the underlying or primary cause decreased during the first year of the COVID-19 pandemic, whereas mortality rates with cancer as a contributing cause increased, according to a new study published by Zhao et al in JCO Oncology Practice. The findings demonstrated...
Digital Breast Tomosynthesis May Improve Breast Cancer Screening Performance in Community Settings
Researchers have found that digital breast tomosynthesis may have improved breast cancer screening performance in community practices and could be effective at identifying more invasive cancers compared with digital mammography, according to a new study published by Lee et al in Radiology. The...
Statewide Survey May Provide Insight Into Cancer-Related Knowledge, Beliefs, and Behaviors of Hispanic Individuals in Indiana
A new survey of Hispanic adults residing in Indiana may present a snapshot of their cancer-related knowledge, beliefs, and behaviors and provide guidance for the future development of tailored cancer screening messaging and prevention strategies, according to a study published by Espinoza-Gutarra...
Cancer Susceptibility Germline Pathogenic Variants Among Older Patients
Hereditary cancer syndromes are caused by a pathogenic variant in cancer susceptibility genes, which overall account for approximately 10% of all cancers. Carriers of pathogenic variants are at an increased risk of developing cancer during their lifetime. Genomic cancer risk assessment makes it...
Addition of Ipilimumab to Nivolumab in Recurrent or Metastatic Head and Neck Cancer
As reported in JAMA Oncology by Kevin J. Harrington, MBBS, PhD, and colleagues, the phase II CheckMate 714 trial has shown that the addition of ipilimumab to nivolumab did not improve objective response rate as first-line treatment in patients with recurrent or metastatic squamous cell carcinoma of ...
Consensus Molecular Subtypes as Markers for Maintenance Therapy Regimens for RAS Wild-Type Metastatic Colorectal Cancer
In an analysis of the German phase II PanaMa trial reported in the Journal of Clinical Oncology, Stahler et al evaluated consensus molecular subtypes as prognostic and predictive biomarkers in patients with RAS wild-type metastatic colorectal cancer receiving fluorouracil and leucovorin with or...
GD2-CAR T Cells for Relapsed or Refractory High-Risk Neuroblastoma
In a single-institution Italian phase I/II trial reported in The New England Journal of Medicine, Del Bufalo et al found that treatment with chimeric antigen receptor (CAR) T cells targeting the disialoganglioside GD2 expressed on tumor cells (GD2-CART01) produced responses in pediatric patients...
Novel Device May Be Safe, Effective Chemotherapy Delivery System for Patients With Muscle-Invasive Bladder Cancer Who Are Unfit for Standard Therapy
Researchers have found that the novel intravesical chemotherapy delivery system TAR-200 may be safe and effective for patients with advanced muscle-invasive bladder cancer who are medically unfit for standard treatment, according to a new study published by Tyson et al in The Journal of Urology....
Financial Toxicity of Cancer May Impact Partner’s Quality of Life
Researchers have discovered that the financial impact of an individual’s cancer diagnosis may also impact a partner’s health-related quality of life, according to a new study published by Ghazal et al in JAMA Network Open. “When you think of key developmental milestones young adults expect to...
Arlene O. Siefker-Radtke, MD, on Urothelial Cancer: Emerging Therapies
Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, provides an overview of the emerging treatments for urothelial cancer, including several new agents in the antibody-drug conjugate and tyrosine kinase inhibitor classes. She describes the clinical activity and...
Prior CTLA-4 Inhibition May Influence Response to PD-1 Inhibitors in Patients With Advanced Melanoma
Researchers have found that responses to PD-1 inhibitor treatment in patients with advanced melanoma may depend on whether they had received previous treatment with CTLA-4 inhibitors, according to a new study published by Campbell et al in Cancer Cell. “In our large set of data, features that have...
Combination Therapy May Help Patients With KMT2A-Mutated ALL or AML Overcome BET Inhibitor Resistance
Researchers have developed a novel combination therapy approach to help patients with KMT2A-mutated acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) overcome resistance to bromodomain and extraterminal domain (BET) inhibitors without adding toxicity, according to a novel study...
Study Finds Precursor Pancreatic Lesions Occur Frequently in Healthy Human Pancreases
Pancreatic cancer is a rare disease, accounting for about 3% of all cancers in the United States. It is the deadliest of all solid malignancies, accounting for about 7% of all cancer deaths each year, and carries a 5-year survival rate of just 11.5%. According to the American Cancer Society, in...
Pathologic Complete Response as Surrogate for Event-Free and Overall Survival in Neoadjuvant Trials in HER2-Positive Early Breast Cancer
In a study reported in the Journal of Clinical Oncology, Squifflet et al found that pathologic complete response (pCR) was a weak surrogate for event-free and overall survival in neoadjuvant trials of anti-HER2 therapy in patients with HER2-positive early breast cancer. Study Details In the study,...
Mortality After Colonoscopy-Detected vs Postcolonoscopy-Diagnosed Colorectal Cancer in the VA Health-Care System
In a study reported in JAMA Network Open, Kahi et al found no differences in all-cause or cancer-specific mortality among veterans in the Veterans Affairs (VA) health-care system with colonoscopy-detected colorectal cancer vs those with postcolonoscopy-diagnosed colorectal cancer. Study Details...
Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer
In a prospective cohort study reported in The Lancet Oncology, Asif et al found that endoscopic surveillance may be an alternative to prophylactic total gastrectomy in patients at risk for hereditary diffuse gastric cancer due to germline CDH1 pathogenic variants. Study Details In the study, 270...
Olanzapine to Prevent Chemotherapy-Related Anorexia in Newly Diagnosed Patients With Advanced Cancers
In an Indian single-center study reported in the Journal of Clinical Oncology, Sandhya et al found that olanzapine was associated with weight gain and improved appetite vs placebo in patients receiving chemotherapy for newly diagnosed locally advanced or metastatic gastric,...
T-DXd in HER2-Expressing Advanced or Recurrent Uterine Carcinosarcoma
In a Japanese phase II trial (STATICE) reported in the Journal of Clinical Oncology, Nishikawa et al found that fam-trastuzumab deruxtecan-nxki (T-DXd) showed activity in patients with HER2-expressing advanced or recurrent uterine carcinosarcoma. Study Details In the multicenter trial, 32 evaluable ...
Interaction of H pylori Infection and Germline Pathogenic Variants in Risk for Gastric Cancer
In a Japanese study reported in The New England Journal of Medicine, Usui et al found that Helicobacter pylori infection affected the risk of gastric cancer in patients with predisposing germline pathogenic variants, including variants in homologous recombination genes. As stated by the...
Azacitidine in Combination With Trametinib May Be Effective for Pediatric Patients With JMML
Researchers have found that the hypomethylating agent azacitidine plus the MEK inhibitor trametinib may be a promising new combination to treat patients with juvenile myelomonocytic leukemia (JMML), according to a preclinical study published by Pasupuleti et al in Molecular Therapy. Background JMML ...
Healthy Lifestyles May Be Associated With Reduced Mortality Risk in Pediatric Cancer Survivors
Researchers have provided strong evidence that a healthy lifestyle may significantly reduce mortality in adults who have survived pediatric cancer, according to a new study published by Dixon et al in The Lancet. The findings are among the first to reveal that the specific primary causes of...
Researchers Identify Potential Biomarkers of Response to Immunotherapy in Patients With Renal Cell Carcinoma
Researchers have revealed that the number of tumor-infiltrating lymphocytes, the state of necrosis, and mutations to the tumor-suppressor gene PBRM1 form a biomarker signature that may predict how patients with renal cell carcinoma will respond to immunotherapy, according to a novel study published ...
USPSTF Announces New Leadership
The U.S. Preventive Services Task Force (USPSTF) recently announced the appointments of Michael J. Barry, MD, as Chair, and Michael Silverstein, MD, MPH, as Vice Chair. Wanda K. Nicholson, MD, MPH, MBA, will remain in her role as Vice Chair. Dr. Barry will assume the role of Chair from Carol M....
City of Hope to Rebrand Cancer Treatment Centers of America Locations to Reflect Transition to National System
City of Hope in Duarte, California, recently announced that its subsidiary, Cancer Treatment Centers of America (CTCA), will fully transition its clinical locations to City of Hope’s brand. CTCA locations in different cities will now be called City of Hope Atlanta, City of Hope Chicago, and City of ...
Surgeon and Cancer Researcher Kelly M. McMasters, MD, PhD, Celebrates the ‘Miracle of Translational Science’
In this installment of our Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kelly M. McMasters, MD, PhD, who, for the past 27 years, has directed a basic and translational science lab studying adenovirus-mediated cancer gene therapy and melanoma biomarkers....
Elizabeth M. Jaffee, MD, FAACR, to Receive 2023 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
The American Association for Cancer Research (AACR) will honor Elizabeth M. Jaffee, MD, FAACR, AACR Past President, with the 2023 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the 2023 AACR Annual Meeting, to be held on April 14–19 in Orlando,...
Nobel Laureate Carolyn R. Bertozzi, PhD, to Receive 2023 AACR Award for Outstanding Achievement Cancer Research
The American Association for Cancer Research (AACR) will honor Nobel Laureate Carolyn R. Bertozzi, PhD, with the 2023 AACR Award for Outstanding Achievement in Chemistry in Cancer Research during the 2023 AACR Annual Meeting on April 14–19 in Orlando, Florida. Dr. Bertozzi’s award lecture will be...
Yes, You Should Attend the 2023 ASCO Annual Meeting
The questions I am challenged to answer are twofold: (1) Should you attend the 2023 ASCO Annual Meeting? (2) If you attend, how is your time best spent? Most people agree scientific conferences are important venues for cancer researchers and clinicians to share and discuss research findings,...
Genetics Likely Caused My Small Cell Lung Cancer
When I was diagnosed with lung cancer, in 2007, I asked the physician not to tell me the type, stage, or prognosis. I was about to start nursing school and was aware enough about the disease to know that not many people survived. I’ve since discovered that I had stage 3B small cell lung cancer,...
Abemaciclib Expanded Indication for Adjuvant Use in HR-Positive, HER2-Negative, Node-Positive Early Breast Cancer
On March 3, 2023, abemaciclib was approved for use with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with hormone receptor (HR)-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence.1 Abemaciclib was previously approved...
Heavy Toll From Prior Authorization Exceeds Alleged Benefits, According to AMA Survey
The approval process health insurers impose on medical services or drugs is generating a toll that exceeds the purported benefits, according to a physician survey recently released by the American Medical Association (AMA) and shared in a letter to federal health officials.1 Although health...
President Biden Prioritizes Cancer Research, Access to Care in FY 2024 Budget Proposal
On March 9, 2023, President Joseph Biden released his proposed Fiscal Year (FY) 2024 federal budget, with an emphasis on increased funding for medical research and expanded access to health insurance. The proposal allocates $48.3 billion for the National Institutes of Health (NIH), an $811 million ...
Effect of Smoking Cessation After Diagnosis of Renal Cell Carcinoma on Disease Progression and Survival Outcomes
In a Russian single-institution prospective cohort study reported in the Journal of Clinical Oncology, Sheikh et al found that quitting smoking after a diagnosis of renal cell carcinoma (RCC) was associated with improved disease progression and survival outcomes among patients. Study Details The...
EAU and ASCO Release Collaborative Guidelines on Penile Cancer
Penile cancer is a rare disease with an incidence that is rising globally. Driven by a goal to offer clinicians and patients guidance on the management of this rare condition, ASCO collaborated with the European Association of Urology (EAU) to develop new guidelines on its diagnosis and treatment....
Kerin Adelson, MD, Named MD Anderson Chief Quality and Value Officer
The University of Texas MD Anderson Cancer Center has announced the appointment of Kerin Adelson, MD, as the institution’s Chief Quality and Value Officer. An accomplished clinician and researcher with extensive leadership experience in cancer care, Dr. Adelson will also hold a faculty appointment...
Summing It Up: Neoadjuvant Therapy in Triple-Negative Disease
Here is how Dr. Sharma summed up the current state of neoadjuvant therapy in triple-negative breast cancer: The addition of an immune checkpoint inhibitor to neoadjuvant chemotherapy improves long-term outcomes. This strategy can produce a modest improvement in pathologic complete response and a...
Lymphoma Research Foundation Establishes Kanti R. Rai, MD, Clinical Scholar Program for the Ongoing Study of CLL
The Lymphoma Research Foundation (LRF) has announced the creation of the Kanti R. Rai, MD, Clinical Scholar Program to fund the ongoing study of lymphoma and chronic lymphocytic leukemia (CLL). Established in recognition of the global leadership of Kanti R. Rai, MD, in the field of lymphoma and CLL ...
Which Patients With Breast Cancer Can Omit Radiotherapy?
Although advances in radiation therapy have rendered this treatment modality more tolerable, they have not completely eliminated the burden of radiation-related toxicity. In an ideal setting, clinicians would be able to identify patients whose risk of recurrence is sufficiently low that they can...
